Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-… Read more
Citius Pharmaceuticals Inc (CTXR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.153x
Based on the latest financial reports, Citius Pharmaceuticals Inc (CTXR) has a cash flow conversion efficiency ratio of -0.153x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.88 Million) by net assets ($77.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Citius Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Citius Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Citius Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Citius Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WISE iTech Co. Ltd
KQ:065370
|
-0.015x |
|
Allane SE
F:LNSX
|
N/A |
|
seha corporation
KO:027970
|
0.076x |
|
Young Heung I&
KO:012160
|
0.000x |
|
i(x) Net Zero Plc
PINK:IXNZF
|
N/A |
|
Ferronordic AB (publ)
ST:FNM
|
-0.029x |
|
Wolftank Group AG
XETRA:WAH
|
0.201x |
|
FoundPac Group Bhd
KLSE:5277
|
0.072x |
Annual Cash Flow Conversion Efficiency for Citius Pharmaceuticals Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Citius Pharmaceuticals Inc from 2011 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $77.53 Million | $-26.55 Million | -0.342x | +10.01% |
| 2024-09-30 | $74.10 Million | $-28.20 Million | -0.381x | -19.74% |
| 2023-09-30 | $91.43 Million | $-29.06 Million | -0.318x | -15.91% |
| 2022-09-30 | $103.43 Million | $-28.36 Million | -0.274x | -50.15% |
| 2021-09-30 | $132.78 Million | $-24.25 Million | -0.183x | +63.68% |
| 2020-09-30 | $33.67 Million | $-16.93 Million | -0.503x | +1.44% |
| 2019-09-30 | $24.38 Million | $-12.44 Million | -0.510x | -25.61% |
| 2018-09-30 | $27.87 Million | $-11.32 Million | -0.406x | -11.83% |
| 2017-09-30 | $21.95 Million | $-7.97 Million | -0.363x | -3.20% |
| 2016-09-30 | $16.77 Million | $-5.90 Million | -0.352x | -109.37% |
| 2015-09-30 | $-635.21K | $-2.39 Million | 3.755x | +295.18% |
| 2014-09-30 | $-741.93K | $-705.05K | 0.950x | +530.18% |
| 2013-09-30 | $93.27K | $-20.60K | -0.221x | -149.83% |
| 2012-09-30 | $-45.85K | $-20.32K | 0.443x | -49.14% |
| 2011-09-30 | $-23.84K | $-20.78K | 0.872x | -- |